Anti-neutrophil cytoplasmic autoantibody pathogenicity revisited: Pathogenic versus non-pathogenic anti-neutrophil cytoplasmic autoantibody

Nephrology Dialysis Transplantation

Volumn 29, Issue 4, 2014, Pages 739-745

  Land, Judith ^a   Rutgers, Abraham ^a   Kallenberg, Cees G M ^a  

^a UNIVERSITY MEDICAL CENTER GRONINGEN   (Netherlands)

Author keywords

ANCA; epitope; pathogenic; regulatory B cells; vasculitis

Indexed keywords

MYELOBLASTIN; MYELOPEROXIDASE; NEUTROPHIL CYTOPLASMIC ANTIBODY; REACTIVE OXYGEN METABOLITE;

ANTIBODY SPECIFICITY; ANTIBODY TITER; ANTIGEN ANTIBODY REACTION; B LYMPHOCYTE; CELL ACTIVATION; CELL ADHESION; CELL MIGRATION; DEGRANULATION; DISEASE ACTIVITY; EPITOPE MAPPING; NEUTROPHIL; NONHUMAN; PATHOGENICITY; PRIORITY JOURNAL; REGULATORY MECHANISM; REVIEW; T LYMPHOCYTE;

ANCA; EPITOPE; PATHOGENIC; REGULATORY B CELLS; VASCULITIS;

ANIMALS; ANTI-NEUTROPHIL CYTOPLASMIC ANTIBODY-ASSOCIATED VASCULITIS; ANTIBODIES, ANTINEUTROPHIL CYTOPLASMIC; AUTOIMMUNITY; HUMANS; NEUTROPHILS; PEROXIDASE;

EID: 84897467636     PISSN: 09310509     EISSN: 14602385     Source Type: Journal    
DOI: 10.1093/ndt/gft416     Document Type: Review

References (59)

1. Jennette JC, Falk RJ. Small-vessel vasculitis. N Engl J Med 1997; 337: 1512-1523
2. Davies DJ, Moran JE, Niall JF et al. Segmental necrotising glomerulonephritis with antineutrophil antibody: Possible arbovirus aetiology? Br Med J (Clin Res Ed) 1982; 285: 606
3. Hagen EC, Daha MR, Hermans J et al. Diagnostic value of standardized assays for anti-neutrophil cytoplasmic antibodies in idiopathic systemic vasculitis. EC/BCR Project for ANCA Assay Standardization. Kidney Int 1998; 53: 743-753
4. Lyons PA, Rayner TF, Trivedi S et al. Genetically distinct subsets within ANCA-Associated vasculitis. N Engl J Med 2012; 367: 214-223
5. Franssen CF, Stegeman CA, Kallenberg CG et al. Antiproteinase 3-And antimyeloperoxidase-Associated vasculitis. Kidney Int 2000; 57: 2195-2206
6. Jennette JC, Falk RJ, Bacon PA et al. 2012 revised International Chapel Hill Consensus Conference Nomenclature of Vasculitides. Arthritis Rheum 2013; 65: 1-11
7. Wiesner O, Russell KA, Lee AS et al. Antineutrophil cytoplasmic antibodies reacting with human neutrophil elastase as a diagnostic marker for cocaine-induced midline destructive lesions but not autoimmune vasculitis. Arthritis Rheum 2004; 50: 2954-2965
8. Kain R, Exner M, Brandes R et al. Molecular mimicry in pauci-immune focal necrotizing glomerulonephritis. Nat Med 2008; 14: 1088-1096
9. Kain R, Tadema H, McKinney EF et al. High prevalence of autoantibodies to hLAMP-2 in anti-neutrophil cytoplasmic antibody-Associated vasculitis. J Am Soc Nephrol 2012; 23: 556-566
10. Roth AJ, Brown MC, Smith RN et al. Anti-LAMP-2 antibodies are not prevalent in patients with antineutrophil cytoplasmic autoantibody glomerulonephritis. J Am Soc Nephrol 2012; 23: 545-555
11. Xiao H, Heeringa P, Hu P et al. Antineutrophil cytoplasmic autoantibodies specific for myeloperoxidase cause glomerulonephritis and vasculitis in mice. J Clin Invest 2002; 110: 955-963
12. Little MA, Smyth CL, Yadav R et al. Antineutrophil cytoplasm antibodies directed against myeloperoxidase augment leukocyte-microvascular interactions in vivo. Blood 2005; 106: 2050-2058
13. Pfister H, Ollert M, Fröhlich LF et al. Antineutrophil cytoplasmic autoantibodies against the murine homolog of proteinase 3 (Wegener autoantigen) are pathogenic in vivo. Blood 2004; 104: 1411-1418
14. Van der Geld YM, Hellmark T, Selga D et al. Rats and mice immunised with chimeric human/mouse proteinase 3 produce autoantibodies to mouse Pr3 and rat granulocytes. Ann Rheum Dis 2007; 66: 1679-1682
15. Primo VC, Marusic S, Franklin CC et al. Anti-PR3 immune responses induce segmental and necrotizing glomerulonephritis. Clin Exp Immunol 2010; 159: 327-337
16. Little MA, Al-Ani B, Ren S et al. Anti-proteinase 3 anti-neutrophil cytoplasm autoantibodies recapitulate systemic vasculitis in mice with a humanized immune system. PLoS One 2012; 7: E28626
17. Falk RJ, Terrell RS, Charles LA et al. Anti-neutrophil cytoplasmic autoantibodies induce neutrophils to degranulate and produce oxygen radicals in vitro. Proc Natl Acad Sci USA 1990; 87: 4115-4119
18. Savage CO, Pottinger BE, Gaskin G et al. Autoantibodies developing to myeloperoxidase and proteinase 3 in systemic vasculitis stimulate neutrophil cytotoxicity toward cultured endothelial cells. Am J Pathol 1992; 141: 335-342
19. Radford DJ, Luu NT, Hewins P et al. Antineutrophil cytoplasmic antibodies stabilize adhesion and promote migration of flowing neutrophils on endothelial cells. Arthritis Rheum 2001; 44: 2851-2861
20. Kessenbrock K, Krumbholz M, Schönermarck U et al. Netting neutrophils in autoimmune small-vessel vasculitis. Nat Med 2009; 15: 623-625
21. Wegener's Granulomatosis Etanercept Trial (WGET) Research Group. Etanercept plus standard therapy for Wegener's granulomatosis. N Engl J Med 2005; 352: 351-361
22. Bansal PJ, Tobin MC. Neonatal microscopic polyangiitis secondary to transfer of maternal myeloperoxidase-Antineutrophil cytoplasmic antibody resulting in neonatal pulmonary hemorrhage and renal involvement. Ann Allergy Asthma Immunol 2004; 93: 398-401
23. Silva F, Specks U, Sethi S et al. Successful pregnancy and delivery of a healthy newborn despite transplacental transfer of antimyeloperoxidase antibodies from a mother with microscopic polyangiitis. Am J Kidney Dis 2009; 54: 542-545
24. Jayne DRW, Gaskin G, Rasmussen N et al. Randomized trial of plasma exchange or high-dosage methylprednisolone as adjunctive therapy for severe renal vasculitis. J Am Soc Nephrol 2007; 18: 2180-2188
25. Boomsma MM, Stegeman CA, van der Leij MJ et al. Prediction of relapses in Wegener's granulomatosis by measurement of antineutrophil cytoplasmic antibody levels: A prospective study. Arthritis Rheum 2000; 43: 2025-2033
26. Finkielman JD, Merkel PA, Schroeder D et al. Antiproteinase 3 antineutrophil cytoplasmic antibodies and disease activity in Wegener granulomatosis. Ann Intern Med 2007; 147: 611-619
27. Tomasson G, Grayson PC, Mahr AD et al. Value of ANCA measurements during remission to predict a relapse of ANCA-Associated vasculitis-A meta-Analysis. Rheumatol Oxf Engl 2012; 51: 100-109
28. Cui Z, Zhao M, Segelmark M et al. Natural autoantibodies to myeloperoxidase, proteinase 3, and the glomerular basement membrane are present in normal individuals. Kidney Int 2010; 78: 590-597
29. Xu P-C, Cui Z, Chen M et al. Comparison of characteristics of natural autoantibodies against myeloperoxidase and anti-myeloperoxidase autoantibodies from patients with microscopic polyangiitis. Rheumatol Oxf Engl 2011; 50: 1236-1243
30. Mulder AH, Stegeman CA, Kallenberg CG. Activation of granulocytes by anti-neutrophil cytoplasmic antibodies (ANCA) in Wegener's granulomatosis: A predominant role for the IgG3 subclass of ANCA. Clin Exp Immunol 1995; 101: 227-232
31. Nowack R, Grab I, Flores-Suarè z LF et al. ANCA titres, even of IgG subclasses, and soluble CD14 fail to predict relapses in patients with ANCAassociated vasculitis. Nephrol Dial Transplant 2001; 16: 1631-1637
32. Xu P-C, Chen M, Zhao M-H. High potential to reverse the inhibition of myeloperoxidase by ceruloplasmin of anti-myeloperoxidase autoantibodies of IgG3 subclass. Autoimmunity 2012; 45: 218-225
33. Pankhurst T, Nash G, Williams J et al. Immunoglobulin subclass determines ability of immunoglobulin (Ig)G to capture and activate neutrophils presented as normal human IgG or disease-Associated anti-neutrophil cytoplasm antibody (ANCA)-IgG. Clin Exp Immunol 2011; 164: 218-226
34. Hedger N, Stevens J, Drey N et al. Incidence and outcome of pauciimmune rapidly progressive glomerulonephritis in Wessex, UK: A 10-year retrospective study. Nephrol Dial Transplant 2000; 15: 1593-1599
35. Eisenberger U, Fakhouri F, Vanhille P et al. ANCA-negative pauciimmune renal vasculitis: Histology and outcome. Nephrol Dial Transplant 2005; 20: 1392-1399
36. Khan A, Lawson CA, Quinn MA et al. Successful treatment of ANCAnegative Wegener's Granulomatosis with rituximab. Int J Rheumatol 2010; 2010: 846063
37. Jennette JC, Falk RJ, Gasim AH. Pathogenesis of antineutrophil cytoplasmic autoantibody vasculitis. Curr Opin Nephrol Hypertens 2011; 20: 263-270
38. Griffith ME, Coulthart A, Pemberton S et al. Anti-neutrophil cytoplasmic antibodies (ANCA) from patients with systemic vasculitis recognize restricted epitopes of proteinase 3 involving the catalytic site. Clin Exp Immunol 2001; 123: 170-177
39. Williams RC, Jr, Staud R, Malone CC et al. Epitopes on proteinase-3 recognized by antibodies from patients with Wegener's granulomatosis. J Immunol 1994; 152: 4722-4737
40. Van Der Geld YM, Simpelaar A, Van Der Zee R et al. Antineutrophil cytoplasmic antibodies to proteinase 3 in Wegener's granulomatosis: Epitope analysis using synthetic peptides. Kidney Int 2001; 59: 147-159
41. Bruner BF, Vista ES, Wynn DM et al. Anti-neutrophil cytoplasmic antibodies target sequential functional proteinase 3 epitopes in the sera of patients with Wegener's granulomatosis. Clin Exp Immunol 2010; 162: 262-270
42. Erdbrügger U, Hellmark T, Bunch DO et al. Mapping of myeloperoxidase epitopes recognized by MPO-ANCA using human-mouse MPO chimers. Kidney Int 2006; 69: 1799-1805
43. Bruner BF, Vista ES, Wynn DM et al. Epitope specificity of myeloperoxidase antibodies: Identification of candidate human immunodominant epitopes. Clin Exp Immunol 2011; 164: 330-336
44. Roth AJ, Ooi JD, Hess JJ et al. Epitope specificity determines pathogenicity and detectability in ANCA-Associated vasculitis. J Clin Invest 2013; 123: 1773-1783
45. Guex N, Peitsch MC. SWISS-MODEL and the Swiss-PdbViewer: An environment for comparative protein modeling. Electrophoresis 1997; 18: 2714-2723
46. Gou S-J, Xu P-C, Chen M et al. Epitope Analysis of anti-myeloperoxidase antibodies in patients with ANCA-Associated vasculitis. PLoS One 2013; doi: 10.1371/journal.pone.0060530
47. Rudensky AY. Regulatory T cells and Foxp3. Immunol Rev 2011; 241: 260-268
48. Abdulahad WH, Stegeman CA, van der Geld YM et al. Functional defect of circulating regulatory CD4+ T cells in patients withWegener's granulomatosis in remission. Arthritis Rheum 2007; 56: 2080-2091
49. Free ME, Bunch DO, McGregor J et al. ANCA-Associated vasculitis patients have defective Treg function exacerbated by presence of a suppression-resistant effector population. Arthritis Rheum 2013; doi: 10.1002/art.37959
50. Mizoguchi A, Mizoguchi E, Smith RN et al. Suppressive role of B cells in chronic colitis of T cell receptor alpha mutant mice. J Exp Med 1997; 186: 1749-1756
51. Fillatreau S, Sweenie CH, McGeachy MJ et al. B cells regulate autoimmunity by provision of IL-10. Nat Immunol 2002; 3: 944-950
52. Blair PA, Noreña LY, Flores-Borja F et al. CD19(+)CD24(hi)CD38(hi) B cells exhibit regulatory capacity in healthy individuals but are functionally impaired in systemic lupus erythematosus patients. Immunity 2010; 32: 129-140
53. Iwata Y, Matsushita T, Horikawa M et al. Characterization of a rare IL-10-competent B-cell subset in humans that parallels mouse regulatory B10 cells. Blood 2011; 117: 530-541
54. Bunch DO, McGregor JG, Khandoobhai NB et al. Decreased CD5+ B cells in active ANCA vasculitis and relapse after rituximab. Clin J Am Soc Nephrol 2013; 8: 382-391
55. Van de Veen W, Stanic B, Yaman G et al. IgG4 production is confined to human IL-10-producing regulatory B cells that suppress antigen-specific immune responses. J Allergy Clin Immunol 2013; doi: 10.1016/j. jaci.2013.01.014
56. Wilde B, Thewissen M, Damoiseaux J et al. Regulatory B cells in ANCAassociated vasculitis. Ann Rheum Dis 2013; 72: 1416-1419
57. Todd SK, Pepper RJ, Tanna A et al. B regulatory cells are numerically but not functionally impaired in AAV. 16th International Vasculitis and ANCAWorkshop. Presse Méd; 42: Doi: 10.1016/j.lpm.2013.02.019
58. Aybar L, Hogan S, Mcgregor J et al. Functionally effect regulatory B cells in patients with active ANCA vasculitis. 16th International Vasculitis and ANCAWorkshop. Presse Méd; 42: Doi: 10.1016/j.lpm.2013.02.265
59. Lepse N, Abdulahad WH, Rutgers A et al. Characterization of regulatory B cells in ANCA-Associated vasculitis (AAV). 16th International Vasculitis and ANCAWorkshop. Presse Méd; 42: Doi: 10.1016/j.lpm.2013.02.245